NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada (TASE:KMDA), a bio-pharmaceutical company, has submitted its clinical development program to the FDA for its flagship drug, Alpha-1 Antitrypsin (AAT) with its aerosolized (inhaled) form for the treatment of Congenital Emphysema caused by Alpha-1 Antitrypsin Deficiency (AATD). The company plans to commence clinical development in the US concurrently with the trials already underway towards registration in Europe.
